With a market cap of $181.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics for serious diseases worldwide. Headquartered in Thousand Oaks, California, Amgen serves healthcare providers globally and collaborates with major biopharmaceutical partners to expand and advance its pipeline.
Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Amgen fits this criterion perfectly. Its broad portfolio includes leading treatments across inflammation, oncology, cardiovascular disease, bone health, and rare conditions, with well-known products such as Enbrel, Otezla, Prolia, Repatha, and KYPROLIS.